content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
              --------------------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 30, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------    ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ               08540
  ---------------------------------------------------------           ------------
          (Address of Principal Executive Offices)                     (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  <PAGE>
  
  
  ITEM 5.     OTHER EVENTS.
  
       On October 30, 2003,  Matritech,  Inc. and Cytogen Corporation  executed an
  amendment and restatement of the Distribution  Agreement originally entered into
  by the parties on October 18, 2002 (the "Restated  Agreement").  Under the terms
  of the Restated Agreement,  which takes effect on November 8, 2003, Cytogen will
  have a non-exclusive right to sell  NMP22(R)BladderChek(TM)  to urologists until
  December  31, 2003 and an  exclusive  right to continue to sell  BladderChek  to
  oncologists  for the term of the  Restated  Agreement.  The term of the Restated
  Agreement expires on December 31, 2004 and is renewable annually thereafter upon
  the mutual  consent of the  parties.  The parties also have agreed to remove the
  requirement  that Cytogen  sell a minimum  quantity of  BladderChek  in order to
  maintain its exclusivity.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
              (c) Exhibits.
  
              EXHIBIT NO.      DESCRIPTION
              -----------      -----------
  
                 99.1          Press Release of Cytogen Corporation dated November
                               3, 2003.
  
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                CYTOGEN CORPORATION
  
  
  
                                By:   /s/ Michael D. Becker
                                      -----------------------------------------
                                      Michael D. Becker
                                      President and Chief Executive Officer
  
  Dated:   November 3, 2003
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
              EXHIBIT NO.      DESCRIPTION
              -----------      -----------
  
                 99.1          Press release of Cytogen Corporation dated November
                               3, 2003.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k-110303.txt", "description": "FORM 8-K DATED 11/03/03", "secsgml_size_bytes": 3525}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03973314"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
              --------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 30, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------    ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ               08540
  ---------------------------------------------------------           ------------
          (Address of Principal Executive Offices)                     (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 5.     OTHER EVENTS.
  
       On October 30, 2003,  Matritech,  Inc. and Cytogen Corporation  executed an
  amendment and restatement of the Distribution  Agreement originally entered into
  by the parties on October 18, 2002 (the "Restated  Agreement").  Under the terms
  of the Restated Agreement,  which takes effect on November 8, 2003, Cytogen will
  have a non-exclusive right to sell  NMP22(R)BladderChek(TM)  to urologists until
  December  31, 2003 and an  exclusive  right to continue to sell  BladderChek  to
  oncologists  for the term of the  Restated  Agreement.  The term of the Restated
  Agreement expires on December 31, 2004 and is renewable annually thereafter upon
  the mutual  consent of the  parties.  The parties also have agreed to remove the
  requirement  that Cytogen  sell a minimum  quantity of  BladderChek  in order to
  maintain its exclusivity.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
              (c) Exhibits.
  
              EXHIBIT NO.      DESCRIPTION
              -----------      -----------
  
                 99.1          Press Release of Cytogen Corporation dated November
                               3, 2003.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                CYTOGEN CORPORATION
  
                                By:   /s/ Michael D. Becker
                                      -----------------------------------------
                                      Michael D. Becker
                                      President and Chief Executive Officer
  
  Dated:   November 3, 2003
  EXHIBIT INDEX
  
              EXHIBIT NO.      DESCRIPTION
              -----------      -----------
  
                 99.1          Press release of Cytogen Corporation dated November
                               3, 2003.